Close
Close
Finance News

Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017

2.8
2.8 from 5 votes
Wednesday, September 13, 2017

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the company was named to Fortune magazine's list of fastest growing companies for 2017. In Fortune's annual rankings, Jazz was named the 78th fastest growing company.

"We are honored to be recognized with some of the most innovative companies in the world," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "Our continued growth is a testament to our hard-working, talented employees who are dedicated to bringing innovative therapies to market for life-threatening or complex conditions that have few if any treatment options."

Fortune magazine's 100 fastest-growing companies are publicly traded companies ranked by revenue growth rate, EPS growth rate and three-year annualized total return for the period ended June 30, 2017. The overall rank is based on the sum of these three ranks.

Jazz - which was recognized by Fortune as the fastest growing company in 2013 - is a rapidly growing international biopharmaceutical company that is investing in optimizing the growth of its key products and advancing and expanding its R&D pipeline with a goal of bringing new therapeutic options to patients.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and VyxeosTM (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinaze® and Defitelio® (defibrotide) in countries outside the U.S. For more information, please visit www.jazzpharmaceuticals.com.

Source: Jazz Pharmaceuticals plc
2.8
2.8 from 5 votes
Free Newsletter
Trending News